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SHORT REPORTS Transvaginal compared with transvesical ultrasonography for recovery of oocytes for in vitro fertilisation
Oocyte recovery guided by transvaginal ultrasonography has been introduced into in vitro fertilisation units and compares favourably with laparoscopic oocyte recovery. 2 The transition from laparoscopy to ultrasonography may, however, account for part of this difference-for example, anaesthetic requirements and risks of pneumoperitoneum are reduced. In Oxford the in vitro fertilisation unit is an outpatient service and used transvesical ultrasonography3 until transvaginal scanning was introduced. Thus we were able to make a direct assessment of the value of oocyte recovery by transvaginal scanning.
Patients, methods, and results
We report the results of 100 consecutive cycles of in vitro fertilisation. There was a definite transition between the final 50 women, undergoing transvesical ultrasonography and the first 50 women undergoing transvaginal ultrasonography (February-March 1987 and April-June 1987, respectively) . The date when oocyte recovery by vaginal scanning was to be introduced was not known when the cycles of treatment were booked, so clinical factors did not affect the composition of the groups. Clinical and laboratory methods were unchanged over both periods. This unit uses norethisterone to schedule cycles and a fixed stimulation regimen to predetermine the day of oocyte recovery.4 Thus any differences in outcome cannot be attributed to subjective decision making about the timing of oocyte recovery, except in a few cycles in each group in which buserelin was used to desensitise the pituitary (transvesical scanning, seven; vaginal scanning, four). An ATL 100 scanner with 3 5 MHz sector probe and needle guide was used in transvesical scanning; a Phillips R1550 XP S scanner with a 5 MHz vaginal probe fitted with the Phillips smooth contour needle guide was used in transvaginal scanning. All recoveries of oocytes were performed with 17 gauge needles, the women being sedated only with intravenous pethidine and diazepam. The policy of the unit is to aim to transfer a maximum of three embryos, with exceptionally four embryos transferred when four poor quality embryos have resulted. In this series six women received four' embryos (transvesical scanning, two; vaginal scanning, four).
The groups were similar clinically and in their responses to stimulation (table) . The numbers of oocytes recovered and fertilised per recovery were significantly higher with transvaginal than transvesical ultrasonography (p<0-0001 for both cases Spearman's rank coefficient). The number of embryos transferred was significantly different between the two groups (p<0-0001, Spearman's rank coefficient), so, although the rate of clinical pregnancy in women receiving more than two embryos was not different between the two groups (transvesical scanning, 36%; transvaginal scanning, 39%), the proportion of the group undergoing transvaginal scanning who received more than two embryos was 
Comment
The attraction of transvaginal scanning is that it provides more detailed imaging and removes the undoubted distress and unpredictable delays to patients associated with techniques that require a full bladder. Our results confirmed expectations, and we immediately transferred to oocyte recovery by transvaginal scanning. Our initial experience produced results superior to our accumulated experience over about 300 cycles with transvesical scanning. The transvaginal method improved yields at each step of in vitro fertilisation, with a higher proportion of women receiving the optimal number of embryos and a higher proportion of cycles resulting in pregnancy. Since the introduction of transvaginal methods the low cost in vitro fertilisation unit in Oxford' has achieved results comparable with those of leading centres, indicating that small units setting up in vitro fertilisation programmes should consider adopting transvaginal methods from the outset.
Effect ofhigh dose somatostatin analogue on growth hormone concentrations in acromegaly Octreotide, a somatostatin analogue, given subcutaneously successfully reduces growth hormone concentrations in acromegaly, but not to within the normal range (<5 mIU/l).'-s Unfortunately, somatostatin also suppresses plasma insulin concentrations and can impair glucose tolerance.2 3 In view of this we compared the biochemical effects of increasing doses of octreotide in patients with acromegaly.
Patients, methods, and results
After their informed consent had been obtained six patients with active acromegaly were given octreotide 0 3, 1-5, or 3 mg daily in divided doses by subcutaneous injection at 0800, 1600, and 2200. A control profile was taken, and then the patients were given each dose for three days, during which blood was taken for measurement of growth hormone, insulin, and glucose concentrations at fixed times (n= 15) over 24 hours. Standard meals were provided on each test day. In a long term study four of the patients continued to take octreotide 1000 [tg thrice daily for a mean of four months (range three to six).
The table shows the fall in 24 hour growth hormone and insulin concentrations with the three doses ofoctreotide compared with the pretreatment concentrations. Compared with the lowest dose regimen, the highest dose caused a significant reduction in both variables; there was no other significant difference among the three doses. In addition, there was no significant change in mean glucose
